NCT06728124View on ClinicalTrials.gov

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

630

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Obesity/Overweight
Interventions
DRUG

GZR18

Used as specified in the protocol

OTHER

Placebo

Administered the same volume as GZR18

Sponsors
All Listed Sponsors
lead

Gan & Lee Pharmaceuticals.

INDUSTRY